- Home
- SMTI vs LUNG Comparison
SMTI vs LUNG Comparison
Compare SMTI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- LUNG
- Stock Information
- Founded
- SMTI 1982
- LUNG 1995
- Country
- SMTI United States
- LUNG United States
- Employees
- SMTI N/A
- LUNG N/A
- Industry
- SMTI Medical/Dental Instruments
- LUNG Industrial Specialties
- Sector
- SMTI Health Care
- LUNG Health Care
- Exchange
- SMTI Nasdaq
- LUNG Nasdaq
- Market Cap
- SMTI 297.2M
- LUNG 299.3M
- IPO Year
- SMTI N/A
- LUNG 2020
- Fundamental
- Price
- SMTI $35.69
- LUNG $7.37
- Analyst Decision
- SMTI Strong Buy
- LUNG Strong Buy
- Analyst Count
- SMTI 2
- LUNG 7
- Target Price
- SMTI $47.00
- LUNG $12.64
- AVG Volume (30 Days)
- SMTI 22.3K
- LUNG 284.5K
- Earning Date
- SMTI 05-12-2025
- LUNG 04-30-2025
- Dividend Yield
- SMTI N/A
- LUNG N/A
- EPS Growth
- SMTI N/A
- LUNG N/A
- EPS
- SMTI N/A
- LUNG N/A
- Revenue
- SMTI $78,056,873.00
- LUNG $83,789,000.00
- Revenue This Year
- SMTI $35.26
- LUNG $17.96
- Revenue Next Year
- SMTI $20.79
- LUNG $18.35
- P/E Ratio
- SMTI N/A
- LUNG N/A
- Revenue Growth
- SMTI 24.66
- LUNG 22.01
- 52 Week Low
- SMTI $26.00
- LUNG $5.46
- 52 Week High
- SMTI $39.08
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- SMTI 58.72
- LUNG 46.93
- Support Level
- SMTI $32.59
- LUNG $7.65
- Resistance Level
- SMTI $34.92
- LUNG $8.12
- Average True Range (ATR)
- SMTI 1.37
- LUNG 0.47
- MACD
- SMTI 0.36
- LUNG -0.07
- Stochastic Oscillator
- SMTI 100.00
- LUNG 23.03
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.